Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.

Abstract excerpt

Among inborn errors of immunity (IEIs), some conditions are characterized by inflammation and autoimmunity at the front line and are particularly challenging to treat. Monogenic diseases associated with gain-of-function mutations in genes critical for cytokine signaling through the JAK-STAT pathway belong to this group. These conditions represent good candidates for treatment with JAK inhibitors. Type I...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Disease Management
• Share to Drug Development
• Share to Drug Evaluation, Preclinical